To ensure that endocrinologists, gastroenterologists, hepatologists, primary care physicians, and all other HCPs, who are in a position to identify and care for patients at risk of developing NAFLD and/or NASH, are familiar with this guideline, clinicians require education about how to implement current AACE recommendations in their practice and thus identify patients early to prevent the development of liver fibrosis progression to cirrhosis, and comorbidities.
Upon successful completion of the program, participants should be better able to:
- Identify the diagnosis and management of NAFLD and NASH as the hepatic manifestation of the metabolic syndrome.
- Describe noninvasive tests currently used and in development for identifying patients with NAFLD and NASH, and those at high risk for clinically significant liver fibrosis.
- Review the efficacy of various treatments for NAFLD and NASH, including pharmacotherapy such as GLP-1 RA.
- Apply the latest management recommendations in clinical practice from the AACE Clinical Practice Guideline on NAFLD and NASH.
The target audience for this activity is intended for HCPs involved in treating patients with NASH/NAFLD, including endocrinologists, gastroenterologists, hepatologists, primary care physicians, and advanced practice professionals (nurse practitioners, physician assistants, etc.
Physicians and Physician Assistants
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.
Please allow two weeks for MOC points to appear within your account on the ABIM website. Participation information will be shared.
Nurses
American Association of Clinical Endocrinology is approved by the California Board of Registered Nursing, Provider Number 17762, for 3 contact hours.
All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Planners
- Diana Barb, MD, Clinical Associate Professor, University of Florida, Gainesville, Florida
No relevant financial relationships - Kenneth Cusi, MD, FACE, FACP, Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida
Disclosures: Consultant: Allergan Pharmaceuticals, AstraZeneca, Axcella, Bristol Myers Squibb, Boehringer Ingelheim, Cirius, Coherus, Deuterex, Echosens, Eli Lilly, Fractyl, Genentech, Genfit, Madrigal, Merck, Novo Nordisk, Prosciento, Zydus
Grant/Research Support: Inventiva, National Institutes of Health, Echosens, Inventiva, National Institutes of Health, Novo Nordisk, Zydus,Nordic - Scott Isaacs, MD, FACE, FACP, Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia
No relevant financial relationships - Sangeeta Kashyap, MD, Professor of Medicine Cleveland Clinic Lerner College of Medicine, Associate Program Director for Endocrinology, Diabetes and Metabolism Fellowship, Associate Editor of Journal of Clinical Endocrinology and Metabolism
Disclsoures: Chair of medication committee for GI Dynamics endobarrier trial
- Kenneth Cusi, MD, FACE, FACP, Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, Florida
Disclosures: Consultant: Allergan Pharmaceuticals, AstraZeneca, Axcella, Bristol Myers Squibb, Boehringer Ingelheim, Cirius, Coherus, Deuterex, Echosens, Eli Lilly, Fractyl, Genentech, Genfit, Madrigal, Merck, Novo Nordisk, Prosciento, Zydus
Grant/Research Support: Inventiva, National Institutes of Health, Echosens, Inventiva, National Institutes of Health, Novo Nordisk, Zydus,Nordic -
Romina Lomonaco, MD, assistant professor of medicine, Division of Endocrinology, Diabetes and Metabolism, The University of Florida, Gainesville, Florida
Disclosures: No relevant financial relationships
- Sangeeta Kashyap, MD, Professor of Medicine Cleveland Clinic Lerner College of Medicine, Associate Program Director for Endocrinology, Diabetes and Metabolism Fellowship, Associate Editor of Journal of Clinical Endocrinology and Metabolism
Disclsoures: Chair of medication committee for GI Dynamics endobarrier trial - Zobair M. Younossi MD, MPH, FACP, FACG, AGAF, FAASLD, President, Inova Medicine Services, Chairman, Clinical Research, Inova Health System, Professor and Chairman, Department of Medicine, Inova Fairfax Medical Campus
Disclosures: NovoNordisk Consultant